Adaptive platform trials : the impact of common controls on type one error and power
Platform trials offer a framework to study multiple interventions in one trial with the opportunity of opening and closing arms. The use of common controls can increase efficiency as compared to individual controls. The need for multiplicity adjustment because of common controls is currently a debate among researchers, pharmaceutical companies, and regulators. The impact of common controls on the type one error in a fixed platform trial, i.e. when all treatments start and end recruitment at the same time, has been discussed in the literature before. We complement these findings by investigating the impact of a common control on the type one error and power in a flexible platform trial, i.e. when one arm joins the platform later. We derived the correlation of test statistics to assess the impact of the overlap and compared the results to a trial with individual controls. Furthermore, we evaluate the power, and the impact of multiplicity adjustment on the power in fixed and flexible platform trials. These methodological considerations are complemented by a regulatory guideline review. With multiple arms, the FWER is inflated when no multiplicity adjustment is applied. However, the FWER inflation is smaller with common controls than with individual controls. Even after multiplicity adjustment, a trial with common controls is often beneficial in terms of sample size and power. However, in some cases, the trial with common controls loses the efficiency gain and it might be advisable to run a separate trial rather than joining a platform trial.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Journal of biopharmaceutical statistics - (2023) vom: 21. Nov., Seite 1-18 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nguyen, Quynh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Common control |
|---|
| Anmerkungen: |
Date Revised 30.11.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/10543406.2023.2275765 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364817496 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364817496 | ||
| 003 | DE-627 | ||
| 005 | 20231226100243.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10543406.2023.2275765 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1215.xml |
| 035 | |a (DE-627)NLM364817496 | ||
| 035 | |a (NLM)37990470 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nguyen, Quynh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adaptive platform trials |b the impact of common controls on type one error and power |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Platform trials offer a framework to study multiple interventions in one trial with the opportunity of opening and closing arms. The use of common controls can increase efficiency as compared to individual controls. The need for multiplicity adjustment because of common controls is currently a debate among researchers, pharmaceutical companies, and regulators. The impact of common controls on the type one error in a fixed platform trial, i.e. when all treatments start and end recruitment at the same time, has been discussed in the literature before. We complement these findings by investigating the impact of a common control on the type one error and power in a flexible platform trial, i.e. when one arm joins the platform later. We derived the correlation of test statistics to assess the impact of the overlap and compared the results to a trial with individual controls. Furthermore, we evaluate the power, and the impact of multiplicity adjustment on the power in fixed and flexible platform trials. These methodological considerations are complemented by a regulatory guideline review. With multiple arms, the FWER is inflated when no multiplicity adjustment is applied. However, the FWER inflation is smaller with common controls than with individual controls. Even after multiplicity adjustment, a trial with common controls is often beneficial in terms of sample size and power. However, in some cases, the trial with common controls loses the efficiency gain and it might be advisable to run a separate trial rather than joining a platform trial | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Common control | |
| 650 | 4 | |a platform trial | |
| 650 | 4 | |a power | |
| 650 | 4 | |a type I error | |
| 700 | 1 | |a Hees, Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Hofner, Benjamin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of biopharmaceutical statistics |d 1991 |g (2023) vom: 21. Nov., Seite 1-18 |w (DE-627)NLM012811432 |x 1520-5711 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:21 |g month:11 |g pages:1-18 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10543406.2023.2275765 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 21 |c 11 |h 1-18 | ||